Rodney R. Miles, MD, PhD

Professor, University of Utah School of Medicine

Specialties

• Non-Hodgkin lymphoma
• Pediatric hematologic malignancies

Education

• Medical Degree—University of Nebraska Medical Center
• Doctorate Degree—Cell Biology, University of Nebraska Medical Center
• Residency—Pathology, University of Utah School of Medicine
• Fellowship—Hematopathology, University of Michigan

Certification/Affiliations

• American Board of Pathology (Anatomic and Clinical Pathology, Hematology)

Research Interests

• Biological subtypes of adult and pediatric non-Hodgkin lymphomas
• Lymphoblastic leukemia and lymphoma

Awards

• 2015 Warren G. Sanger Award for Translational Lymphoma Research, 5th International Symposium on Childhood, Adolescent, and Young Adult Non-Hodgkin’s Lymphoma, Varese, Italy.

Recent Publications

• Teachey DT, Devidas M, Wood BL, et al. Children's Oncology Group Trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma. J Clin Oncol. 2022;40(19):2106-2118.
• Underdown MJ, Miles RR, Gross TG, et al. Importance of clinical correlation in the diagnosis of pediatric B-cell lymphomas. Pediatr Blood Cancer. 2022;69(3):e29527.
• Li P, Venkatachalam S, Ospina Cordona D, et al. A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm. Blood Adv. 2022;6(2):405-409.
• Burke GAA, Minard-Colin V, Aupérin A, et al. Dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab therapy in children and adolescents with primary mediastinal B-cell lymphoma: a multicenter phase II trial. J Clin Oncol. 2021;39(33):3716-3724.
• Goldman S, Barth M, Shiramizu B, et al. A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma. Leukemia. 2021;35(10):2994-2997.
• Mangum DS, Meyer JA, Mason CC, et al. Association of combined focal 22q11.22 deletion and IKZF1 alterations with outcomes in childhood acute lymphoblastic leukemia. JAMA Oncol. 2021;7(10):1521-1528.
• Xu X, Paxton CN, Hayashi RJ, et al. Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma. Blood Adv. 2021;5(14):2890-2900.
• Viola D, Dona A, Caserta E,  et al. Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. Leukemia. 2021;35(1):189-200.
• Hayashi RJ, Winter SS, Dunsmore KP, et al. Successful outcomes of newly diagnosed T lymphoblastic lymphoma: results from Children's Oncology Group AALL0434. J Clin Oncol. 2020;38(26):3062-3070.
• Minard-Colin V, Aupérin A, Pillon M, et al. Rituximab for high-risk, mature B-cell non-Hodgkin's lymphoma in children. N Engl J Med. 2020;382(23):2207-2219.
• Radhakrishnan SV, Luetkens T, Scherer SD, et al. CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. Nat Commun. 2020;11(1):798.
• Atanackovic D,  Yousef S, Shorter C, et al. In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. Leukemia. 2020;34(1):317-321.
• Pearson ADJ, Scobie N, Norga K, et al. ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children. Euro J Cancer. 2019 Mar;110:74-85.
• Patel AB, Miles RR, Deininger MW. Lysozyme nephropathy in chronic myelomonocytic leukemia. Clin Case Rep. 2019;7(6):1263-1264.
• Jafek JL, Shakya A, Tai PY, et al. Transcription factor Oct1 protects against hematopoietic stress and promotes acute myeloid leukemia. Exp Hematol. 2019;76:38-48.
• Galardy PJ, Bedekovics T, Macintyre E, et al. Lymphoma diagnostics: getting more from less. 2019;185(6):1136-1141.
• Chu Y, Lee S, Shah T, et al. Ibrutinib significantly inhibited Bruton’s thyrosine kinase (BTK) phosphorylation, in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model. Oncoimmunology. 2018;8(1):e1512455.
• Chisholm KM, Mohlman J, Liew M, et al. IRF4 translocation status in pediatric follicular and diffuse large B-cell lymphoma patients enrolled in Children’s Oncology Group trials. Pediatr Blood Cancer. 2019;66(8):e27770.
• Borga C, Park G, Foster C, et al. Simultaneous B and T cell acute lymphoblastic leukemias in zebrafish driven by transgenic MYC: implications for oncogenesis and lymphopoiesis. Leukemia. 2019;33(2):333-347.
• Zabriskie MS, Antelope O, Verma AR, et al. A novel AGGF1-PDGFRb fusion in pediatric T-cell acute lymphoblastic leukemia. Haematologica. 2018;103(2):e87–e91.
• Merzianu M, Groman A, Hutson A, et al. Trends in bone marrow sampling and core biopsy specimen adequacy in the United States and Canada: a multicenter study. Am J Clin Pathol. 2018;150(5):393-405.
• Elkeeb D, Hopkins Z, Miles RR, et al. Ominous cutaneous presentation of acute myeloid leukemia without peripheral blood involvement upon initial presentation and relapse: case report and literature review. Eur J Dermatol. 2018;28(6): 809-817.
• Tharkar-Promod S, Johnson DP, Bennett SE, et al. HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia. Leukemia. 2018;32(1):49-60.